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Figure 1 Two patients, both with acute inferior ST-segment-elevation myocardial infarction 
treated successfullywith primary percutaneous coronary intervention (PCI). Each patient had 
thrombolysis in myocardial infarction (TIMI) grade 3 flow at the end of PCI. Cardiac magnetic 
resonance (CMR) imaging was performed at 3 days postreperfusion in both patients. (A) Patient 
with normal index of microcirculatory resistance (IMR), low coronary flow reserve (CFR) , an 
inferior infarct but no microvascular obstruction (MVO) or myocardial haemorrhage on CMR 2 
days later. The diagnostic guide wire study of culprit artery microvascular function at the end of 
primary PCI indicated an abnormal CFR (1.6) but a preserved IMR (10). Late gadolinium contrast-
enhanced CMR revealed an inferior infarct with no evidence of MVO (middle image, yellow 
arrows). (B) A patient with high IMR, low CFR and haemorrhagic infarction on CMR. The diagnostic 
guide wire study of culprit microvascular function immediately after primary PCI indicated severe 
microcirculatory dysfunction (IMR 59 and CFR 1.2). T2*-CMR (far right image) revealed myocardial 
haemorrhage (white arrow) within the infarct core. Contrast-enhanced CMR revealed MVO (middle 
image, red arrow) within the bright area of infarction. The MVO within the infarct core spatially 
corresponded with the myocardial haemorrhage.
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In patients with ST-segment elevation 
myocardial infarction (STEMI), 
primary percutaneous coronary interven-
tion (PCI) successfully restores normal 
antegrade flow in the infarct-related artery 
in nearly 99% of patients. However, 
approximately half of all STEMI patients 
have failed microcirculatory reperfusion, 
as reflected by microvascular obstruction 
(MVO), and one-third have myocardial 
haemorrhage, reflecting severe, ‘down-
stream’, potentially irreversible, 
microvascular injury.1
MVO is the ‘Achilles Heel’ of 
primary PCI, yet clinicians are generally 
unaware of the occurrence of MVO and 
myocardial haemorrhage in their patients, 
unless cardiac magnetic resonance (CMR) 
is performed. However, CMR is not done 
routinely. Other established investiga-
tions for detecting failure of myocardial 
reperfusion, such as angiographic, or 
electrocardiographic parameters, lack 
sensitivity and reproducibility in clinical 
practice.
Immediate invasive measurement of 
microvascular resistance at the time of 
PCI has the potential to optimise the 
approach to therapeutic interventions 
by: (1) acutely identifying patients at 
high risk of MVO who are most likely to 
benefit from adjunct therapy, for example, 
with glycoprotein IIb/IIIa inhibitors, (2) 
targeting novel therapies in clinical trials 
to patients with evidence of microvascular 
dysfunction and (3) allowing immediate 
evaluation of the efficacy of reperfusion 
therapy. However, invasive tests of the 
efficacy of myocardial reperfusion in 
STEMI patients have been hampered by a 
number of methodological and technical 
shortcomings. The ideal acute invasive test 
of microvascular perfusion and dysfunc-
tion should be reliable and reproducible, 
operator independent and easy to perform 
with standard PCI equipment.
Currently, the index of microvascular 
resistance (IMR) has the most exten-
sive evidence base to support its use as 
a reference test of culprit artery micro-
vascular function in patients with acute 
STEMI.IMR is a thermodilution-derived 
index, measured using a guide wire that 
combines a pressure and temperature 
sensor. Specifically, IMR is defined as 
distal coronary pressure multiplied by the 
mean transit time of a 3 mL bolus of saline 
at room temperature during maximal 
coronary hyperaemia. IMR measured 
at the end of primary PCI reproducibly 
reflects the extent of MVO, observed on 
CMR. Moreover, an IMR >40 (postpri-
mary PCI) reliably predicts mortality and 
heart failure (independent of infarct size) 
at 1 year.2 3 Importantly, IMR derived at 
peak hyperaemia has less haemodynamic 
dependence than coronary flow reserve 
(CFR), providing a more reproducible 
assessment of the microcirculation in 
patients with STEMI (figure 1).
CFR reflects epicardial and microvas-
cular vasodilator capacity (unlike IMR, 
which measures microvascular resistance); 
however, CFR does not allow discrimina-
tion between the two components. In a 
previous study, Carrick et al showed that 
IMR >40 and CFR ≤2 combined did not 
confer incremental prognostic value in 
STEMI patients.3 IMR was more closely 
associated with myocardial haemorrhage, 
whereas CFR (not IMR) was discrimina-
tive in patients with less severe (potentially 
reversible) MVO.4
In their Heart manuscript, de Waard 
et al5 present their findings on hyper-
aemic microvascular resistance (HMR), 
compared with CFR, measured imme-
diately after PCI for MI (n=176), as a 
predictor of clinical outcome and MVO 
(referred to as microvascular injury in 
their paper). HMR may be considered 
analogous to IMR, as they are both 
measures of microvascular resistance. 
However, unlike IMR, HMR is derived 
from pressure Doppler flow guide wires, 
thus negating the need for manual injec-
tion of saline. Specifically, HMR is the 
ratio between hyperaemic mean distal 
pressure and hyperaemic average Doppler 
flow peak velocity. A reliable Doppler 
flow velocity tracing is required for 
measurement; however, Doppler flow 
velocity signals may be inconsistent and 
are particularly influenced by the wire 
tip position. Indeed, in the current study, 
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8% of invasive measurements had to 
be excluded, due to poor Doppler flow 
signals, or iatrogenic coronary dissection 
in one patient.5 Compared with IMR, 
Doppler guide wire measurements have a 
steeper learning curve, the measurements 
are technically challenging, the amount of 
time involved to acquire the data may be 
longer and in general the Doppler wire is 
more expensive than the wire that is used 
to measure IMR. For all of these reasons, 
HMR is currently a method used in 
research protocols rather than in routine 
practice.
IMR also has drawbacks. A potential 
limitation of using IMR to assess MVO 
is that (unlike HMR) the location of the 
sensor influences transit time so should 
be constant during repeated measure-
ments and in general standardised to 
6–9 cm from the guide catheter. IMR has 
a weak association with LV mass (unlike 
CFR).4 Thus, intervessel variability in 
IMR measurement may exist, and the 
territorial extent of coronary microcir-
culatory disruption could be a potential 
confounding variable. Theoretically, for 
measured IMR to reflect, true microvas-
cular resistance collateral flow needs to 
be taken into account, by correcting for 
wedge pressure, which is measured by 
balloon occlusion of the coronary artery. 
However, in the context of acute STEMI 
uncorrected-measured IMR correlates 
strongly with wedge-corrected IMR.6 The 
explanation for why collateral arteries can 
potentially complicate the measurement 
of microvascular resistance (ie, IMR or 
HMR) is that flow arising from collat-
eral arteries distal to the sensor generates 
pressure that is transmitted through the 
coronary artery, hence overestimation 
of the distal pressure measurement and 
microvascular resistance.
De Waard et al5 found that CFR <1.5 
was predictive for the composite endpoint 
(death and hospitalisation for heart 
failure), HR: 3.5, 95% CI 1.1 to 10.8, but 
not for the separate components of death 
and heart failure hospitalisations. HMR 
≥3.0 mm  Hg·cm-1-s was more strongly 
predictive for the composite endpoint, 
HR: 7.0, 95% CI 1.5 to 33.7, was an 
independent predictor for its individual 
components and remained independently 
associated with the composite outcome 
after adjustment for baseline and proce-
dural characteristics. Furthermore, 
compared with CFR, HMR was a superior 
predictor of MVO (defined by CMR). The 
authors therefore concluded that HMR 
is superior to CFR, for identifying MI 
patients with MVO who are at high risk of 
adverse clinical outcome.
Like IMR, HMR represents an emerging 
approach for the immediate assessment 
for MVO in the catheter laboratory, but 
given the considerations around its use, it 
may be most useful for research purposes 
rather than unselected real-world prac-
tice. Alternatively, IMR would seem better 
disposed for use in real-world practice. 
The findings of de Waard et al5 comple-
ment those of previously published 
studies3 4 in a number of important 
ways. First, a broader range of MI types 
were included (ie, both STEMI (n=130) 
and non-STEMI (n=46) patients were 
analysed) with stable patients (without 
coronary artery disease) serving as a refer-
ence cohort. Second, it was a multicentre 
study. Third, microvascular resistance was 
measured using Doppler, instead of ther-
modilution.
The limitations of the current study5 
need to be borne in mind. Importantly, 
the sample size was modest, raising the 
possibility of type 1 error, consecutive 
patients were not recruited and nearly 1 in 
10 recordings were ruled out due to issues 
with data acquisition.
Further work in this area is warranted. 
In particular, the findings of the current 
study5 should be further evaluated in 
larger cohorts of patients. Several invasive 
measures of the microcirculation have been 
described in STEMI cohorts, including 
IMR,4 HMR,5 zero-flow pressure7 and 
absolute microvascular resistance (which 
in contrast to IMR requires estimation of 
myocardial mass).8 Each of these indices 
has pros and cons. To date, only IMR, 
as a measure of infarct pathology and 
predictor of mortality, has been validated 
in large cohorts, and IMR is comparatively 
straightforward to measure. These tests 
of microvascular injury have potential to 
enable a ‘stratified medicine’ approach, in 
which patients identified to be at higher 
risk of adverse outcome may be stratified 
for more intensive therapy. This idea is 
being prospectively evaluated in T-TIME 
(NCT02257294), which is a phase 2, 
randomised, placebo-controlled clinical 
trial of reduced doses of intracoronary 
alteplase in selected higher risk patients 
with STEMI.
IMR and HMR have potential as 
novel indices for patient selection and 
as biomarkers of the efficacy of therapy; 
however, more research is needed to 
assess whether IMR and HMR are modi-
fiable. Further research is also warranted 
to validate IMR and HMR as novel tests 
of the efficacy of intracoronary therapies; 
should this be the case, the results would 
support the use of IMR and HMR as a 
biomarker of the efficacy of therapeutic 
interventions designed to improve 
myocardial reperfusion, as assessed in 
future trials.
In conclusion, the study by de Waard 
et al5 extends the evidence on the patho-
physiological and prognostic importance 
of microvascular dysfunction in the 
culprit artery at the end of PCI. De Waard 
et al5 provide original data on HMR, 
which adds to previous investigations of 
IMR and CFR, in patients with STEMI. 
Studies in larger cohorts are needed to 
explore further the utility of IMR and 
HMR as a therapeutic target during 
primary PCI and to identify and stratify 
higher risk patients for more intensive 
management.
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